Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.

@article{Economou2005InterferonalphaPL,
  title={Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.},
  author={Michael S Economou and Spilios G Manolakopoulos and Thomas-A Trikalinos and Spyros Filis and Sotiris Bethanis and Dimitrios Tzourmakliotis and Alec Avgerinos and Sotiris A Raptis and Epameinondas-V Tsianos},
  journal={World journal of gastroenterology},
  year={2005},
  volume={11 37},
  pages={5882-7}
}
AIM The HBeAg negative form of chronic hepatitis B (CHB) predominates in the Mediterranean area and has a rising frequency in Europe and North America. At present there are three approved therapies for patients with CHB: interferon-alpha (IFN-alpha), lamivudine and adefovir dipivoxil. Unfortunately, none of these drugs are effective in achieving a sustained… CONTINUE READING